Peer-reviewed veterinary case report
Risk of cancer in dogs treated long-term with oclacitinib
By Tennant, Bryn·Published in Companion Animal·2020·MRCVS Capital Diagnostics, SRUC Veterinary Services·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Small animal Review
- Species:
- dog
Plain-English summary
A study looked at how well oclacitinib, a medication for allergic skin problems in dogs, works and whether it might affect the risk of cancer in dogs treated for a long time. Allergic dermatitis can cause itching and skin irritation, and oclacitinib helps by reducing inflammation. While the medication is effective for managing these symptoms, the long-term effects on cancer risk in dogs are still not fully understood. Pet owners should discuss the benefits and risks of this treatment with their veterinarian to make the best choice for their dog's health.
People also search for: dog allergic dermatitis treatment · oclacitinib side effects · dog skin allergy medication
Abstract
Summary: Allergic dermatitis in dogs can be managed using a range of medical therapies including glucocorticoids, ciclosporin, oclacitinib, loviketmab and immunotherapy. Oclacitinib inhibits janus-kinases leading to depressed function of proinflammatory cytokines. Some cytokines protect against tumour development. Oclacitinib may hinder cell proliferation, differentiation, migration, apoptosis and survival. Oclacitinib's impact in dogs who have neoplasia is unclear. The study discussed here has assessed the risk of neoplasia in dogs treated over a long period with oclacitinib.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.12968/coan.2020.0083